Therefore, to expand upon this, WDR5 depletion, combined with chemotherapeutics, could be considered as a promising candidate strategy in anti-CRC therapy to improve clinical outcomes by disrupting stem-like traits of cancer cells and amplifying the toxic effects of chemotherapeutics. The gene discussed is WDR5; the disease is cancer.